ProKidney Reports Q1 Results, Confirms Phase 3 Enrollment On Track, $225M Cash Runway
PROK has more than doubled off its 52-week low of $0.54.
Summary
ProKidney reported first-quarter 2026 financial results, showing cash, cash equivalents, and marketable securities of $224.9 million as of March 31, 2026, down from $270.0 million at year-end 2025. The company projects this liquidity will fund operations into mid-2027. Research and development expenses increased to $33.8 million, primarily due to the ongoing PROACT 1 study, leading to an increased net loss of $42.6 million. On the clinical front, the company reiterated that Phase 3 PROACT 1 enrollment for the surrogate endpoint is on track for completion in mid-2026, with pivotal topline results expected in Q2 2027. This report confirms the previously established FDA alignment on the accelerated approval pathway for rilparencel, as noted in the full-year 2025 results. For a clinical-stage biotech, maintaining a sufficient cash runway and hitting clinical milestones are critical, making this a material update for investors to track.
At the time of this announcement, PROK was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $484.6M. The 52-week trading range was $0.54 to $7.13. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.